Literature DB >> 30765433

Effect of a Behavioral Weight Loss Intervention in People With Serious Mental Illness and Diabetes.

Eva Tseng1,2, Arlene T Dalcin3,2, Gerald J Jerome4, Joseph V Gennusa3, Stacy Goldsholl3, Courtney Cook3, Lawrence J Appel3,2,5, Nisa M Maruthur3,2,5, Gail L Daumit3,2,6,7, Nae-Yuh Wang3,2,5,8.   

Abstract

OBJECTIVE: Given the high prevalence of obesity and diabetes in patients with serious mental illness (SMI) and the lack of evidence on the effects of weight loss programs in SMI patients with diabetes, we evaluated the effectiveness of a behavioral weight loss intervention among SMI participants with and without diabetes. RESEARCH DESIGN AND METHODS: Using data from ACHIEVE, a randomized controlled trial to evaluate the effects of a behavioral weight loss intervention among overweight/obese people with SMI, we assessed and compared weight change from baseline to 18 months in participants with and without diabetes using a longitudinal mixed-effects model.
RESULTS: Of the 291 trial participants, 82 (28.2%) participants had diabetes (34 and 48 in intervention and control groups, respectively) at baseline. Participants with diabetes were more likely to be taking antipsychotics (31.7% vs. 18.7%, P = 0.02). At 18 months, participants in the control group with diabetes lost 1.2 lb (0.6%) of body weight compared with 0.8 lb (0.7%) among those without diabetes. In the intervention group, participants with diabetes lost 13.7 lb (6.6%) of their initial body weight compared with 5.4 lb (2.9%) for those without diabetes. Corresponding net effects (intervention minus control) were 4.6 lb (2.2%) and 12.5 lb (6.0%) net weight reduction over 18 months in the no diabetes and the diabetes subgroups, respectively. However, the between-group difference in intervention effects was statistically nonsignificant (absolute weight change: P-interaction = 0.08; % weight change: P-interaction = 0.10).
CONCLUSIONS: A behavioral weight loss intervention is effective among overweight and obese individuals with SMI regardless of their diabetes status.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30765433      PMCID: PMC6489111          DOI: 10.2337/dc18-2201

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  26 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

2.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.

Authors:  Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

3.  Weight loss for individuals with type 2 diabetes following a very-low-calorie diet in a community-based setting with trained facilitators for 12 weeks.

Authors:  C Rolland; S Lula; C Jenner; L Dyson; I Macdonald; K L Johnston; I Broom
Journal:  Clin Obes       Date:  2013-08-23

Review 4.  Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.

Authors:  Nick Verhaeghe; Jan De Maeseneer; Lea Maes; Cornelis Van Heeringen; Lieven Annemans
Journal:  Int J Behav Nutr Phys Act       Date:  2011-04-11       Impact factor: 6.457

Review 5.  Diabetes mellitus and severe mental illness: mechanisms and clinical implications.

Authors:  Richard I G Holt; Alex J Mitchell
Journal:  Nat Rev Endocrinol       Date:  2014-12-02       Impact factor: 43.330

6.  Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study.

Authors:  L P Voruganti; Z Punthakee; R J Van Lieshout; D MacCrimmon; G Parker; A G Awad; H C Gerstein
Journal:  Schizophr Res       Date:  2007-08-30       Impact factor: 4.939

7.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

8.  Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

Authors:  David B Allison; John W Newcomer; Andrea L Dunn; James A Blumenthal; Anthony N Fabricatore; Gail L Daumit; Mark B Cope; William T Riley; Betty Vreeland; Joseph R Hibbeln; Jonathan E Alpert
Journal:  Am J Prev Med       Date:  2009-04       Impact factor: 5.043

9.  Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial.

Authors:  Sarah S Casagrande; Gerald J Jerome; Arlene T Dalcin; Faith B Dickerson; Cheryl A Anderson; Lawrence J Appel; Jeanne Charleston; Rosa M Crum; Deborah R Young; Eliseo Guallar; Kevin D Frick; Richard W Goldberg; Meghan Oefinger; Joseph Finkelstein; Joseph V Gennusa; Oladapo Fred-Omojole; Leslie M Campbell; Nae-Yuh Wang; Gail L Daumit
Journal:  BMC Psychiatry       Date:  2010-12-13       Impact factor: 3.630

10.  Successful long-term weight loss among participants with diabetes receiving an intervention promoting an adapted Mediterranean-style dietary pattern: the Heart Healthy Lenoir Project.

Authors:  Genevieve G R Embree; Carmen D Samuel-Hodge; Larry F Johnston; Beverly A Garcia; Ziya Gizlice; Kelly R Evenson; Darren A DeWalt; Alice S Ammerman; Thomas C Keyserling
Journal:  BMJ Open Diabetes Res Care       Date:  2017-03-29
View more
  1 in total

1.  Effects of a behavioural weight loss intervention in people with serious mental illness: Subgroup analyses from the ACHIEVE trial.

Authors:  Eleanore Alexander; Emma E McGinty; Nae-Yuh Wang; Arlene Dalcin; Gerald J Jerome; Edgar R Miller; Faith Dickerson; Jeanne Charleston; Deborah R Young; Joseph V Gennusa; Stacy Goldsholl; Courtney Cook; Lawrence J Appel; Gail L Daumit
Journal:  Obes Res Clin Pract       Date:  2019-03-07       Impact factor: 2.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.